LANSING, Mich., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, announced today that the Company's MonsterSilk™ fiber commercialization ramp up program is the subject of a current article in Textile World.
"It is a huge honor to be featured in this month's publication of Textile World," said Kraig CEO and founder, Kim K. Thompson.
"We appreciate the industry exposure for genetically engineered spider silk. As reported, we are working diligently to expand production and bring our product to commercialization. Toward that end, our plan is to both expand our production into additional facilities and increase our fiber production at current facilities," concluded Thompson.
The article can be viewed at the following link: http://www.textileworld.com/Issues/2014/September_October/Quality_Fabric_Of_The_Month/Guided_By_The_Silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc